The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. KalVista Pharmaceuticals Inc shares valued at $51,289 were sold by Sweeny Nicole on Nov 24 ’25. At $13.45 per share, Sweeny Nicole sold 3,813 shares. The insider’s holdings dropped to 39,728 shares worth approximately $0.65 million following the completion of this transaction.
Also, Piekos Brian sold 4,471 shares, netting a total of over 60,139 in proceeds. Following the sale of shares at $13.45 each, the insider now holds 10,529 shares.
Before that, Yea Christopher had sold 4,331 shares from its account. In a trade valued at $58,256, the CHIEF DEVELOPMENT OFFICER traded KalVista Pharmaceuticals Inc shares for $13.45 each. Upon closing the transaction, the insider’s holdings decreased to 4,331 shares, worth approximately $3.67 million.
As published in their initiating research note from JMP Securities on January 31, 2025, KalVista Pharmaceuticals Inc [KALV] has been a Mkt outperform and the price target has been revised to $19. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of December 18, 2024, BofA Securities has initiated its “Buy” rating for KALV. Earlier on June 15, 2020, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for KALV stock.
Analyzing KALV Stock Performance
On last trading session, KalVista Pharmaceuticals Inc [NASDAQ: KALV] rose 11.87% to $16.4. The stock’s lowest price that day was $14.3, but it reached a high of $16.8 in the same session. During the last five days, there has been a surge of approximately 16.31%. Over the course of the year, KalVista Pharmaceuticals Inc shares have jumped approximately 59.69%. Shares of the company reached a 52-week high of $17.28 on 09/11/25 and a 52-week low of $7.30 on 01/13/25.
Support And Resistance Levels for KalVista Pharmaceuticals Inc (KALV)
According to the 24-hour chart, there is a support level at 14.87, which, if violated, would cause prices to drop to 13.33. In the upper region, resistance lies at 17.37. The next price resistance is at 18.33. RSI (Relative Strength Index) is 71.46 on the 14-day chart, showing overbought technical sentiment.
Is KalVista Pharmaceuticals Inc subject to short interest?
Stocks of KalVista Pharmaceuticals Inc saw a sharp steep in short interest on 2025-11-14 dropping by 46072.0 shares to 14.45 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 14.5 million shares. A decline of -0.32% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.01 of the overall float, the days-to-cover ratio (short ratio) decline to 12.01.
Which companies own the most shares of KalVista Pharmaceuticals Inc (KALV)?
In terms of KalVista Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 28 in the next 12 months, up nearly 91.0% from the previous closing price of $14.66. Analysts anticipate KalVista Pharmaceuticals Inc stock to reach 28 by 2025, with the lowest price target being 28. In spite of this, 2 analysts ranked KalVista Pharmaceuticals Inc stock as Buy at the end of 2025. On July 29, 2019, SVB Leerink assigned a price target of “an Outperform” to the stock and initiated coverage with a $31.
